Raghavendra Rao

During the quarter, its total operating income jumped 18.5 percent to Rs 371.60 crore from Rs 313.53 crore in the same period last fiscal.

F&S brings its largest on-site assessment process to Gulf

Frost & Sullivan, the Global Growth Partnership Company, with a reputation of identifying leaders through a structured and systematic process (endorsed by the Industry across the Globe), is proud to bring its largest on-site assessment process to the Gulf - “Value Chain Leadership Awards 2013"

Orchid Chemicals eyes 15-20% growth in FY13

After not so impressive results and a fall in Q4 net profit by 75%, K Raghavendra Rao, CMD, Orchid Chemicals said that the company‘s topline and bottomline performance has been affected mainly due to the repayment of Foreign Currency Convertible Bonds (FCCB).

Pledged shares: Promoters staring down the barrel of a gun

If the downturn in the stock market continues for some more time, promoters of quite a few mid-cap companies risk losing control of their empires.

Orchid promoters pledge more shares with lenders

Orchid on Thursday informed the stock exchanges that its promoters have net pledged an additional 7.05 lakh shares in the last week of June.

Orchid Chem hopes to maintain EBIDTA margin at 24% in FY12

In an interview with CNBC-TV18, Raghavendra Rao, Orchid Chemicals says, the company is guiding 25% growth in the top-line and more than proportionate growth in bottom-line for FY12. “We should touch about USD 500 million in top-line and more than proportionate growth in bottom-line,” he adds.

Orchid Chem FY11 topline up 32%, sees 25% growth in FY12

Orchid Chemicals & Pharmaceuticals’ FY11 (April-March) revenues rose 33% to Rs 1786 crore, ahead of the company’s guidance of Rs 1600 crore. Full year net profit was Rs 156 crore, but cannot be compared to the previous year’s figure of Rs 339, as that included exceptional gains from the sale of the generic injectables unit.